Why is Akums Drugs & Pharmaceuticals Ltd falling/rising?

Recent Price Performance and Market Comparison

Akums Drugs has outperformed its sector and benchmark indices in the short term. Over the past week, the stock surged by 6.58%, more than double the Sensex’s 2.94% gain. Similarly, in the last month, it rose 4.40% compared to the Sensex’s modest 0.59%. Year-to-date, the stock has gained 2.78%, while the Sensex declined by 1.36%. These figures highlight a recent positive momentum that contrasts with the stock’s longer-term underperformance, as it has fallen 16.82% over the past year while the Sensex gained 7.97%.

On the day in question, Akums Drugs outperformed its sector by 2.75%, reaching an intraday high of ₹470, a 5.16% increase. The stock has been on a two-day winning streak, delivering a cumulative 4.5% return. Its price currently sits above the 5-day, 20-day, 50-day, and 100-day moving averages, signalling short- to medium-term strength, although it remains below the 200-day moving average, indicating some longer-term resistance.

Institutional Interest and Valuation Appeal

One of the key drivers behind the recent price rise appears to be increasing institutional participation. Institutional investors have raised their stake by 4% in the previous quarter, now collectively holding 15.55% of the company. This growing confidence from well-resourced investors, who typically conduct thorough fundamental analysis, lends credibility to the stock’s prospects and likely supports the price appreciation.

Additionally, Akums Drugs presents an attractive valuation profile with a price-to-book value of 2.3 and a return on equity (ROE) of 9.7%. While the ROE is moderate, the valuation metrics suggest the stock is reasonably priced relative to its book value, which may be enticing investors seeking value opportunities in the pharmaceuticals sector.

Fundamental Challenges Tempering Long-Term Outlook

Despite the recent gains, Akums Drugs faces significant fundamental headwinds that have weighed on its longer-term performance. Over the last five years, net sales have grown at a modest annual rate of 6.10%, while operating profit has expanded at 17.54%. These growth rates, though positive, are relatively subdued for a pharmaceutical company in a competitive market.

More concerning are the recent quarterly earnings trends. Profit before tax excluding other income (PBT less OI) declined by 49.6% compared to the previous four-quarter average, while net profit after tax (PAT) fell by 50.1% over the same period. This sharp contraction in profitability contrasts starkly with the reported 1362% profit increase over the past year, suggesting volatility and possible one-off factors influencing earnings.

Interest expenses have surged dramatically, growing by 380.25% in the latest six months to ₹46.44 crores, which could be exerting pressure on the company’s bottom line. Such rising financial costs may limit future profitability and investor enthusiasm if not managed effectively.

Investor participation has also shown signs of weakening recently, with delivery volumes on 06 Feb falling by 65.56% against the five-day average. This decline in active trading volume could indicate cautious sentiment among retail investors despite the price rally.

Balancing Short-Term Gains with Long-Term Risks

Akums Drugs & Pharmaceuticals Ltd’s recent price rise reflects a combination of short-term market momentum, institutional buying, and attractive valuation metrics. However, the company’s weak long-term fundamentals, including modest sales growth, declining recent profitability, and rising interest costs, present significant challenges. The stock’s underperformance relative to the broader market over the past year underscores these concerns.

For investors, the current rally may offer an opportunity to capitalise on near-term gains, but caution is warranted given the mixed signals from the company’s financial health. Monitoring upcoming quarterly results and institutional activity will be crucial to assess whether the positive momentum can be sustained or if fundamental weaknesses will reassert pressure on the stock price.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →